Results 1 to 10 of about 438,950 (335)
TYROSINE KINASE INHIBITORS AND INTERFERON
Mediterranean Journal of Hematology and Infectious Diseases, 2014 The use of interferon-a (INF) in chronic myeloid leukemia, when it started in the 80s, was considered as a breakthrough in the therapy of this disease; INF administered alone or in combination with aracytine was the standard choice for treatment for
Maria Dimou, Panagiotis Panagiotidis
doaj +4 more sources
TYROSINE KINASE INHIBITORS AND PREGNANCY
Mediterranean Journal of Hematology and Infectious Diseases, 2014 The management of patients with chronic myeloid leukemia (CML) during pregnancy has became recently a matter of continuous debate. The introduction of the Tyrosine Kinase Inhibitors (TKIs) in clinical practice has dramatically changed the prognosis of ...
Elisabetta Abruzzese +3 more
doaj +5 more sources
Thoracic Cancer, 2021 Background T790M mutation causes resistance to tyrosine kinase inhibitors (TKIs) in approximately 49% of patients with epidermal growth receptor‐mutant non‐small cell lung cancer (NSCLC).
Tadashi Nishimura +12 more
doaj +1 more source
mTORC2 is a tyrosine kinase [PDF]
Cell Research, 2015 The mammalian target of rapamycin (mTOR), a protein kinase, is the centre of huge attention due to its importance in intracellular signaling and in health and disease. In their recent study, Yin et al. show that mTOR can regulate signaling through the insulin-like growth factor 1 receptor and that it possesses a new enzymatic activity - the ability to ...
Christopher G. Proud, Xuemin Wang
openaire +2 more sources
Tyrosine Kinase Receptors in Oncology [PDF]
International Journal of Molecular Sciences, 2020 Tyrosine kinase receptors (TKR) comprise more than 60 molecules that play an essential role in the molecular pathways, leading to cell survival and differentiation. Consequently, genetic alterations of TKRs may lead to tumorigenesis and, therefore, cancer development.
Jorge Esteban-Villarrubia +8 more
openaire +4 more sources
The tyrosine kinase Csk dimerizes through Its SH3 domain. [PDF]
PLoS ONE, 2009 The Src family kinases possess two sites of tyrosine phosphorylation that are critical to the regulation of kinase activity. Autophosphorylation on an activation loop tyrosine residue (Tyr 416 in commonly used chicken c-Src numbering) increases catalytic
Nicholas M Levinson +2 more
doaj +1 more source
Haematologica, 2017 Nearly one-third of patients with acute myeloid leukemia have FMS-like tyrosine kinase 3 mutations and thus have poor survival prospects. Receptor tyrosine kinase anexelekto is critical for FMS-like tyrosine kinase 3 signaling and participates in FMS ...
Peter P. Ruvolo +11 more
doaj +1 more source
Journal of Xenobiotics, 2023 Immune thrombocytopenic purpura (ITP) is an acquired antibody or cell-mediated platelet damage or decreased platelet production. Steroids, IV immunoglobulins (IVIG), and Rho-anti-D antibodies are the commonly used initial treatments for ITP.
Muhammad Ashar Ali +8 more
doaj +1 more source
Tyrosine kinases in rheumatoid arthritis [PDF]
Journal of Inflammation, 2011 Rheumatoid arthritis (RA) is an inflammatory, polyarticular joint disease. A number of cellular responses are involved in the pathogenesis of rheumatoid arthritis, including activation of inflammatory cells and cytokine expression. The cellular responses involved in each of these processes depends on the specific signaling pathways that are activated ...
Hiroshi Okamoto, Akiko Kobayashi
openaire +4 more sources
Nanomedicine of tyrosine kinase inhibitors
Theranostics, 2021 Recent progress in nanomedicine and targeted therapy brings new breeze into the field of therapeutic applications of tyrosine kinase inhibitors (TKIs). These drugs are known for many side effects due to non-targeted mechanism of action that negatively impact quality of patients' lives or that are responsible for failure of the drugs in clinical trials.
Zita Goliasova +9 more
openaire +4 more sources